Posts By: pharmanewsdaily

Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US

Biodesix, a lung cancer diagnostic solutions company, has acquired UK-based Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the US, to expand its blood-based lung cancer diagnostic portfolio. Oncimmune’s US commercial and lab operations, including a Clinical Laboratory Improvement Amendments (CLIA) lab in DeSoto, Kansas, has now been transferred to Biodesix. The Kansas […]

Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators

Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of locally acting immunomodulators targeting autoimmune diseases of the pancreas. The collaboration will bring together the modular biologics and functional immunology expertise of Cambridge-based biotech company and Astellas Pharma’s advanced therapeutics […]

Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

Amplia Pharmatek acquired by NuChem Therapeutics

NuChem Therapeutics has wrapped up the acquisition of Amplia Pharmatek, a Quebec-based drug discovery and development contract research organization (CRO) with a focus on biology. Based in Montreal, NuChem Therapeutics too is a drug discovery and development CRO. The company specializes in synthetic and medicinal chemistry services. Amplia Pharmatek, on the other hand, is a […]

LAVENDER phase 3 clinical trial launched for trofinetide in Rett syndrome by Acadia Pharmaceuticals

US biopharma company Acadia Pharmaceuticals has launched the LAVENDER phase 3 clinical trial to evaluate the efficacy and safety of trofinetide for the treatment of Rett syndrome in girls and young women. Rett syndrome is considered to be a serious and rare neurodevelopmental congenital disorder related to the central nervous system (CNS). Symptoms of Rett […]

Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma

Cellectis said that it has dosed the first patient in a phase 1  study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM). The French gene therapy company began the phase 1 dose-escalation study after getting clearance from the US Food […]

Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome

Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients, aged 1 year and older. The California-based biopharma company is engaged in the development and commercialization of new therapies for debilitating liver diseases. Alagille syndrome […]

Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis

Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]

Pepticom secures investment for AI-driven peptide drug discovery

Israel-based Pepticom, which is engaged in using artificial intelligence (AI) for peptide drug discovery, has raised $5 million in a Series A funding round from the Chartered Group. Pepticom is a spin-out of Yissum, the technology transfer company of The Hebrew University of Jerusalem. The company’s artificial intelligence technology is said to optimize and significantly speed […]

Scroll To Top